{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:23:32Z","timestamp":1782725012827,"version":"3.54.5"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the demographic and imaging factors at baseline and Month 3 (M3) that predict visual or anatomical responses at Month 12 (M12) in the EVEREST-II study for polypoidal choroidal vasculopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Post-hoc analysis of 322 participants in the EVEREST-II study. Patient factors, best-corrected visual acuity (BCVA), treatment, and imaging parameters at baseline and M3 were evaluated with respect to outcomes at M12 using univariate and multivariable analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Younger age (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and lower baseline BCVA (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) were associated with higher BCVA gains at M12. Smaller baseline polypoidal lesion area was associated with higher BCVA gains at M12 only in the ranibizumab monotherapy arm (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008). Central subfield thickness at M3, area of branching vascular network at M3, BCVA at M3, and age were associated with change in BCVA from M3 at M12. Higher odds of fluid-free retina at M12 were associated with lower baseline central subfield thickness (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.006), treatment with combination therapy (baseline and M3 models; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), and absence of subretinal fluid at M3 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Several imaging parameters at baseline and M3 can predict treatment outcome. The interaction between treatment arm and total polypoidal lesion area suggests this feature may assist selecting between initial ranibizumab monotherapy or combination therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002902","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T21:00:48Z","timestamp":1594155648000},"page":"387-392","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY"],"prefix":"10.1097","volume":"41","author":[{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"first","affiliation":[{"name":"Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin S.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramune","family":"Patalauskaite","sequence":"additional","affiliation":[{"name":"Novartis Ireland Ltd, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Margaron","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y. Y.","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/OPTH.S101596","article-title":"One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement","volume":"10","author":"Hirakata","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R5-20250609","first-page":"527","article-title":"Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy","volume":"6","author":"Cheung","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1097\/IAE.0000000000001815","article-title":"Ranibizumab and AFLIBERCEPT for the treatment OF pigment epithelial detachment IN neovascular age-related macular degeneration: data from an observational study","volume":"38","author":"Vaze","year":"2018","journal-title":"Retina"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","article-title":"Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy","volume":"38","author":"Yanagi","year":"2018","journal-title":"Retina"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/IAE.0000000000001776","article-title":"Comparison of optical coherence tomography angiographic changes after anti-vascular endothelial growth factor therapy alone or in combination with photodynamic therapy in polypoidal choroidal vasculopathy","volume":"38","author":"Teo","year":"2018","journal-title":"Retina"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ajo.2013.07.001","article-title":"Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy","volume":"156","author":"Cho","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10384-015-0387-z","article-title":"Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability","volume":"59","author":"Nomura","year":"2015","journal-title":"Jpn J Ophthalmol"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","article-title":"Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","article-title":"Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy","volume":"254","author":"Kim","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1167\/iovs.12-9619","article-title":"Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"53","author":"Jirarattanasopa","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","article-title":"The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration","volume":"3","author":"Cheung","year":"2019","journal-title":"Ophthalmol Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:00:45Z","timestamp":1749484845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002902"}},"subtitle":["Predictors of Visual and Anatomical Response in the EVEREST II Study"],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002902","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,13]]}}}